| __timestamp | Geron Corporation | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 54170000 |
| Thursday, January 1, 2015 | 17793000 | 65378000 |
| Friday, January 1, 2016 | 18761000 | 52263000 |
| Sunday, January 1, 2017 | 19287000 | 35072000 |
| Monday, January 1, 2018 | 18707000 | 27415000 |
| Tuesday, January 1, 2019 | 20893000 | 36983000 |
| Wednesday, January 1, 2020 | 25678000 | 50918000 |
| Friday, January 1, 2021 | 29665000 | 63586000 |
| Saturday, January 1, 2022 | 43628000 | 57967000 |
| Sunday, January 1, 2023 | 69135000 | 53107000 |
| Monday, January 1, 2024 | 23626000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Mesoblast Limited and Geron Corporation from 2014 to 2023. Over this period, Mesoblast consistently reported higher SG&A expenses, peaking in 2015 with a 65% increase compared to Geron. However, Geron showed a dramatic rise in 2023, with expenses surging by 58% from the previous year, surpassing Mesoblast for the first time. This shift highlights Geron's aggressive expansion strategy, while Mesoblast's expenses have gradually decreased by 56% since 2015. The data suggests a strategic pivot for both companies, with Geron investing heavily in growth and Mesoblast focusing on cost efficiency. Missing data for 2024 indicates potential reporting delays or strategic changes. Investors should watch these trends closely as they reflect each company's operational priorities and market positioning.
Breaking Down SG&A Expenses: Amgen Inc. vs Mesoblast Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Mesoblast Limited Trends and Insights
Teva Pharmaceutical Industries Limited and Geron Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Summit Therapeutics Inc. and Geron Corporation
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Geron Corporation Trends and Insights
Selling, General, and Administrative Costs: Exelixis, Inc. vs Mesoblast Limited
Jazz Pharmaceuticals plc vs Mesoblast Limited: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Geron Corporation
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Geron Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Geron Corporation
Comparing SG&A Expenses: Geron Corporation vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Geron Corporation or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?